Metabolic Reprogramming in Hepatocellular Carcinoma: Mechanisms and Therapeutic Implications

Overview

Journal Exp Mol Med

Specialties Biochemistry
Molecular Biology

Date 2025 Mar 2

PMID 40025169

Authors

Sujin Park

Michael N Hall

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma features extensive metabolic reprogramming. This includes alterations in major biochemical pathways such as glycolysis, the pentose phosphate pathway, amino acid metabolism and fatty acid metabolism. Moreover, there is a complex interplay among these altered pathways, particularly involving acetyl-CoA (coenzyme-A) metabolism and redox homeostasis, which in turn influences reprogramming of other metabolic pathways. Understanding these metabolic changes and their interactions with cellular signaling pathways offers potential strategies for the targeted treatment of hepatocellular carcinoma and improved patient outcomes. This review explores the specific metabolic alterations observed in hepatocellular carcinoma and highlights their roles in the progression of the disease.

References

Dayton T, Gocheva V, Miller K, Israelsen W, Bhutkar A, Clish C . Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes Dev. 2016; 30(9):1020-33. PMC: 4863734. DOI: 10.1101/gad.278549.116. View

Gluchowski N, Becuwe M, Walther T, Farese Jr R . Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2017; 14(6):343-355. PMC: 6319657. DOI: 10.1038/nrgastro.2017.32. View

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

Ikeda M, Okusaka T, Mitsunaga S, Ueno H, Tamai T, Suzuki T . Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2015; 22(6):1385-94. DOI: 10.1158/1078-0432.CCR-15-1354. View

Abou-Alfa G, Meyer T, Cheng A, El-Khoueiry A, Rimassa L, Ryoo B . Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1):54-63. PMC: 7523244. DOI: 10.1056/NEJMoa1717002. View

El-Khoueiry A, Sangro B, Yau T, Crocenzi T, Kudo M, Hsu C . Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389(10088):2492-2502. PMC: 7539326. DOI: 10.1016/S0140-6736(17)31046-2. View

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

Macheda M, Rogers S, Best J . Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2004; 202(3):654-62. DOI: 10.1002/jcp.20166. View

Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss T . GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol. 2009; 174(4):1544-52. PMC: 2671384. DOI: 10.2353/ajpath.2009.080596. View

10.

Sun H, Yu X, Wu W, Chen J, Shi M, Zheng L . GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma. PLoS One. 2016; 11(12):e0168907. PMC: 5201247. DOI: 10.1371/journal.pone.0168907. View

11.

Kim Y, Jeong D, Pak K, Han M, Kim J, Liangwen L . SLC2A2 (GLUT2) as a novel prognostic factor for hepatocellular carcinoma. Oncotarget. 2017; 8(40):68381-68392. PMC: 5620264. DOI: 10.18632/oncotarget.20266. View

12.

Huang Q, Tan Y, Yin P, Ye G, Gao P, Lu X . Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 2013; 73(16):4992-5002. DOI: 10.1158/0008-5472.CAN-13-0308. View

13.

Robey R, Hay N . Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006; 25(34):4683-96. DOI: 10.1038/sj.onc.1209595. View

14.

DeWaal D, Nogueira V, Terry A, Patra K, Jeon S, Guzman G . Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin. Nat Commun. 2018; 9(1):446. PMC: 5792493. DOI: 10.1038/s41467-017-02733-4. View

15.

Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R . Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma. Dig Dis Sci. 2014; 60(2):420-6. PMC: 4323170. DOI: 10.1007/s10620-014-3364-3. View

16.

Xu S, Herschman H . A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers. Cancer Res. 2019; 79(23):5907-5914. DOI: 10.1158/0008-5472.CAN-19-1789. View

17.

Arora K, Pedersen P . Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem. 1988; 263(33):17422-8. View

18.

David C, Chen M, Assanah M, Canoll P, Manley J . HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature. 2009; 463(7279):364-8. PMC: 2950088. DOI: 10.1038/nature08697. View

19.

Chen Z, Lu X, Wang Z, Jin G, Wang Q, Chen D . Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma. Oncotarget. 2015; 6(4):2538-48. PMC: 4385869. DOI: 10.18632/oncotarget.2991. View

20.

Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J . Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. Gastroenterology. 2013; 144(5):1066-1075.e1. PMC: 3633738. DOI: 10.1053/j.gastro.2013.01.054. View